Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment

Circulation. 2002 Feb 5;105(5):627-32. doi: 10.1161/hc0502.102965.

Abstract

Background: The physiological effects of ACE inhibitors may act in part through a kinin-dependent mechanism. We investigated the effect of chronic ACE-inhibitor treatment on functional kinin B(1)- and B(2)-receptor expression, which are the molecular entities responsible for the biological effects of kinins.

Methods and results: Rats were subjected to different 6-week treatments using various mixtures of the following agents: ACE inhibitor, angiotensin AT(1)-receptor antagonist, and B(1)- and B(2)-receptor antagonists. Chronic ACE inhibition induced both renal and vascular B(1)-receptor expression, whereas B(2)-receptor expression was not modified. Furthermore, with B(1)-receptor antagonists, it was shown that B(1)-receptor induction was involved in the hypotensive effect of ACE inhibition. Using microdissection, we prepared 10 different nephron segments and found ACE-inhibitor-induced expression of functional B(1)-receptors in all segments. ACE-inhibitor-induced B(1)-receptor induction involved homologous upregulation, because it was prevented by B(1)-receptor antagonist treatment. Finally, using B(2)-receptor knockout mice, we showed that ACE-inhibitor-induced B(1)-receptor expression was B(2)-receptor independent.

Conclusions: This study provides the first evidence that chronic ACE-inhibitor administration is associated with functional vascular and renal B(1)-receptor induction, which is involved in ACE-inhibitor-induced hypotension. The observed B(1)-receptor induction in the kidney might participate in the known renoprotective effects of ACE inhibition.

MeSH terms

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
  • Animals
  • Biphenyl Compounds / pharmacology
  • Blood Pressure / drug effects
  • Blood Pressure / physiology*
  • Bradykinin / analogs & derivatives*
  • Bradykinin / pharmacology
  • Bradykinin Receptor Antagonists
  • Dinoprostone / biosynthesis
  • Drug Administration Schedule
  • Enzyme Activation / drug effects
  • Hypotension / chemically induced
  • Hypotension / metabolism
  • Irbesartan
  • Kidney / cytology
  • Kidney / drug effects
  • Kidney / metabolism
  • Male
  • Mice
  • Mice, Knockout
  • Nephrons / cytology
  • Nephrons / drug effects
  • Nephrons / metabolism
  • Organ Specificity
  • RNA, Messenger / metabolism
  • Ramipril / administration & dosage*
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Angiotensin, Type 1
  • Receptor, Bradykinin B1
  • Receptor, Bradykinin B2
  • Receptors, Bradykinin / genetics
  • Receptors, Bradykinin / metabolism*
  • Tetrazoles / pharmacology
  • Time

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Biphenyl Compounds
  • Bradykinin Receptor Antagonists
  • R 715
  • RNA, Messenger
  • Receptor, Angiotensin, Type 1
  • Receptor, Bradykinin B1
  • Receptor, Bradykinin B2
  • Receptors, Bradykinin
  • Tetrazoles
  • icatibant
  • Irbesartan
  • Dinoprostone
  • Ramipril
  • Bradykinin